Ireland - English - HPRA (Health Products Regulatory Authority)

abbvie limited - botulinum toxin type a - powder and solvent for solution for injection - other muscle relaxants, peripherally acting agents; botulinum toxin

Ireland - English - HPRA (Health Products Regulatory Authority)

abbvie limited - botulinum toxin type a - powder for solution for injection - other muscle relaxants, peripherally acting agents; botulinum toxin

Ireland - English - HPRA (Health Products Regulatory Authority)

abbvie limited - botulinum toxin type a - powder for solution for injection - other muscle relaxants, peripherally acting agents; botulinum toxin

United States - English - NLM (National Library of Medicine)

allergan, inc. - pancrelipase lipase (unii: 8myc33932o) (pancrelipase lipase - unii:8myc33932o), pancrelipase protease (unii: 3560d81v50) (pancrelipase protease - unii:3560d81v50), pancrelipase amylase (unii: yoj58o116e) (pancrelipase amylase - unii:yoj58o116e) - pancrelipase lipase 10440 [usp'u] -       viokace  tablets, in combination with a proton pump inhibitor,  is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.       none.       risk summary  published data from case reports with pancrelipase use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. pancrelipase is minimally absorbed systematically; therefore, maternal use is not expected to result in fetal exposure to the drug. animal reproduction studies have not been conducted with pancrelipase.       the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.       ri

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

allergan ltd - levobunolol hydrochloride - eye drops - 5mg/1ml

United States - English - NLM (National Library of Medicine)

allergan, inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - assisted reproductive technology crinone 8% is indicated for progesterone supplementation or replacement as part of an assisted reproductive technology ("art") treatment for infertile women with progesterone deficiency. secondary amenorrhea crinone 4% is indicated for the treatment of secondary amenorrhea. crinone 8% is indicated for use in women who have failed to respond to treatment with crinone 4%. crinone should not be used in individuals with any of the following conditions: - known sensitivity to crinone (progesterone or any of the other ingredients) - undiagnosed vaginal bleeding - liver dysfunction or disease - known or suspected malignancy of the breast or genital organs - missed abortion - active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders crinone ® 4% and crinone ® 8% ("kri-noan") (progesterone gel) for vaginal use only you will need the following supplies: see figure a. step 1.  remove the applicator from the

Australia - English - Department of Health (Therapeutic Goods Administration)

allergan australia pty ltd - botulinum toxin - type a; botulinum toxin, type a; botulinum toxin, type a -

United States - English - NLM (National Library of Medicine)

allergan, inc. - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine 10 mg - sarafem is indicated for the treatment of premenstrual dysphoric disorder (pmdd) [see   clinical studies (14.1) ].   the effectiveness of sarafem in long-term use (that is, for more than 6 months) has not been systematically evaluated in placebo-controlled trials. the use of sarafem for extended periods should be periodically re-evaluated for the individual patient [see   dosage and administration (2.1) ]. the use of maois intended to treat psychiatric disorders with sarafem or within 5 weeks of stopping treatment with sarafem is contraindicated because of an increased risk of serotonin syndrome. the use of sarafem within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [se e dosage and administration (2.4)  and warnings and precautions (5.2) ]. starting sarafem in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.5)

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

allergan ltd - polyvinyl alcohol - eye drops - 14mg/1ml

United States - English - NLM (National Library of Medicine)

allergan, inc. - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - fiorinal is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of fiorinal in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. fiorinal is contraindicated under the following conditions: - hypersensitivity or intolerance to aspirin, caffeine, or butalbital. - patients with a hemorrhagic diathesis (e.g., hemophilia, hypoprothrombinemia, von willebrand’s disease, the thrombocytopenias, thrombasthenia and other ill-defined hereditary platelet dysfunctions, severe vitamin k deficiency and severe liver damage). - patients with the syndrome of nasal polyps, angioedema and bronchospastic reactivity to aspirin or other nonsteroidal anti-inflammatory drugs. anaphylactoid reactions have occurred in such patients. - peptic ulcer or other serious gastrointestinal lesions. - patients with porphyria. controlled substance fiorinal